Table 3.
Estrone, Estradiol, and SHBG Concentrations (Geometric Means, 95% Confidence Intervals) at Baseline and 6 Month Follow-up, by Baseline BMI
| BMI <25.0 kg/m2 | |||||||
| ASPIRIN (N=37) | PLACEBO (N=36) | ||||||
| Baseline | 6 months | Change (%) | Baseline | 6 months | Change (%) | P | |
|
Geometric mean
(95% CI) |
Geometric mean
(95% CI) |
Geometric mean
(95% CI) |
Geometric mean
(95% CI) |
||||
| Estrone (pg/mL) |
28.2 (25.8, 30.9) | 27.4 (25.2, 29.8) | −0.9 (−3.1) | 29.8 (27.0, 33.0) | 29.9 (27.1, 32.9) | 0.0 (0.0) | 0.55 |
| Estradiol (pg/mL) |
6.0 (5.3, 6.8) | 6.2 (5.8, 6.8) | 0.2 (3.9) | 6.5 (5.6, 7.4) | 6.2 (5.7, 6.7) | −0.3 (−4.7) | 0.32 |
| Free estradiol (pg/mL) |
0.136 (0.119, 0.156) | 0.142 (0.128, 0.157) | 0.006 (4.0) | 0.144 (0.123, 0.169) | 0.135 (0.121, 0.151) | −0.009 (−5.9) | 0.26 |
| Bioavailable estradiol (pg/mL) |
3.50 (3.07, 3.99) | 3.61 (3.26, 3.99) | 0.11 (3.1) | 3.64 (3.10, 4.28) | 3.44 (3.08, 3.83) | −0.20 (−5.6) | 0.32 |
| SHBG (nmol/L) |
56.3 (50.6, 62.7) | 57.1 (50.8, 64.2) | 0.8 (1.4) | 60.4 (53.2, 68.6) | 62.2 (55.5, 69.8) | 1.8 (2.9) | 0.65 |
| BMI 25.0-29.99 kg/m2 | |||||||
| ASPIRIN (N=21) | PLACEBO (N=22) | ||||||
| Baseline | 6 months | Change (%) | Baseline | 6 months | Change (%) | P | |
|
Geometric mean
(95% CI) |
Geometric mean
(95% CI) |
Geometric mean
(95% CI) |
Geometric mean
(95% CI) |
||||
| Estrone (pg/mL) |
34.3 (29.4, 40.0) | 34.4 (29.5, 40.0) | 0.1 (0.3) | 35.9 (30.9, 41.7) | 36.5 (31.5, 42.2) | 0.6 (1.6) | 0.90 |
| Estradiol (pg/mL) |
8.1 (6.2, 10.5) | 7.4 (6.3, 8.6) | −0.7 (−9.2) | 8.4 (7.1, 9.9) | 9.6 (7.6, 12.2) | 1.2 (14.4) | 0.15 |
| Free estradiol (pg/mL) |
0.206 (0.156, 0.272) | 0.186 (0.154, 0.224) | −0.02 (−9.9) | 0.210 (0.178, 0.249) | 0.244 (0.192, 0.309) | 0.033 (15.9) | 0.13 |
| Bioavailable estradiol (pg/mL) |
5.26 (3.99, 6.93) | 4.72 (3.90, 5.70) | −0.54 (−10.3) | 5.35 (4.51, 6.35) | 6.19 (4.89, 7.85) | 0.85 (15.8) | 0.12 |
| SHBG (nmol/L) |
41.2 (33.9, 50.0) | 42.6 (35.1, 51.7) | 1.4 (3.4) | 44.7 (39.0, 51.2) | 43.0 (37.2, 49.7) | −1.6 (−3.7) | 0.12 |
| BMI ≥ 30 kg/m2 | |||||||
| ASPIRIN (N=17) | PLACEBO (N=10) | ||||||
| Baseline | 6 months | Change (%) | Baseline | 6 months | Change (%) | P | |
|
Geometric mean
(95% CI) |
Geometric mean
(95% CI) |
Geometric mean
(95% CI) |
Geometric mean
(95% CI) |
||||
| Estrone (pg/mL) |
33.9 (30.3, 37.8) | 37.9 (33.7, 42.7) | 4.1 (12.0) | 42.4 (35.2, 51.1) | 40.4 (33.3, 49.0) | −2.0 (−4.7) | 0.22 |
| Estradiol (pg/mL) |
9.5 (8.1, 11.3) | 10.7 (8.0, 14.4) | 1.2 (12.5) | 10.7 (9.1, 12.7) | 10.7 (8.6, 13.4) | 0.0 (0.0) | 0.53 |
| Free estradiol (pg/mL) |
0.256 (0.213, 0.307) | 0.280 (0.210, 0.374) | 0.025 (9.6) | 0.284 (0.231, 0.348) | 0.279 (0.217, 0.359) | −0.005 (−1.7) | 0.56 |
| Bioavailable estradiol (pg/mL) |
6.50 (5.40, 7.83) | 7.14 (5.36, 9.51) | 0.63 (9.7) | 7.20 (5.86, 8.83) | 7.06 (5.51, 9.05) | −0.14 (−1.9) | 0.55 |
| SHBG (nmol/L) |
35.8 (29.5, 43.4) | 38.3 (31.1, 47.3) | 2.6 (7.2) | 37.5 (28.8, 49.0) | 39.8 (30.5, 52.0) | 2.3 (6.0) | 0.88 |
*
P value: GEE model, comparing the change at 6 month follow-up from baseline between Aspirin and Placebo group, stratified by baseline BMI